ORAMED PHARMACEUTICALS INC. (ORMP)
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Oramed Pharmaceuticals Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 41.60M shares outstanding
USOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides.
Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule.
The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Leadership
Avraham Gabay
Chief Financial Officer, Treasurer & Secretary
Benjamin Shapiro
Director
Dr. Arie Mayer
Director
Dr. Daniel Aghion
Director
Employees
13
Country
US
Sector
Healthcare
Website
oramed.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Gabay Avraham | Chief Financial Officer | Sale | 20.0K | $90.2K | Oct 1, 2026 |
 Hexter Joshua | COO & CBO | Sale | 30.0K | $135.3K | Oct 1, 2026 |
 Kidron Miriam | Chief Scientific Officer | Withholding/Transfer | 70.0K | -- | Sep 24, 2026 |
| Kidron Miriam | Chief Scientific Officer | Withholding/Transfer | 100.0K | -- | Sep 24, 2026 |
| Kidron Miriam | Chief Scientific Officer | Withholding/Transfer | 104.0K | -- | Sep 24, 2026 |
| Hexter Joshua | COO & CBO | Withholding/Transfer | 36.0K | -- | Sep 24, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
MERCER GLOBAL ADVISORS INC /ADV | 3.8M | 9.2% | 13F |
Nadav Kidron · may incl. warrants· filed Aug 2025 | 3.1M | 7.5% | 13D |
Aquamarine Financial Ltd | 2.5M | 6.0% | 13F |
Gem Investment Advisors, LLC | 2.0M | 4.8% | 13F |
BlackRock, Inc. | 1.6M | 3.9% | 13F |
 Kidron Miriam Chief Scientific Officer, Director | 1.6M | 3.7% | FORM 4 |
 Hexter Joshua COO & CBO | 1.3M | 3.2% | FORM 4 |
Murchinson Ltd. | 1.3M | 3.1% | 13F |
Leonard Braden Michael · joint filing· may incl. warrants· reaffirmed 13F Aug 2026 | 1.0M | 2.5% | 13G |
BML Capital Management, LLC | 866.3K | 2.1% | 13F |
Insiders
- Gabay AvrahamChief Financial Officer
- Hexter JoshuaCOO & CBO
- Kidron MiriamChief Scientific Officer
- KIDRON NADAVPresident and CEO
- Shapiro BenjaminDirector
- Reznick YehudaDirector
- Mayer ArieDirector
- Aghion DanielDirector
- Sank LeonardDirector
based on 41.60M shares outstanding
US30d Avg
142.39K
60d Avg
172.27K
90d Avg
187.01K